Bright Minds Biosciences Inc (NASDAQ:DRUG) does about 2.68M shares in volume on a normal day but saw 8914092 shares change hands in the recent trading day. The company now has a market cap of 214.17M USD. Its current market price is $48.02, marking an increase of 1.72% compared to the previous close of $47.21. The 52 week high reached by this stock is $79.02 whilst the lowest price level in 52 weeks is $0.93.
Bright Minds Biosciences Inc (DRUG) has a 20-day trading average at $10.13 and the current price is -39.23% off the 52-week high compared with 5063.44% distance from its 52-week low. The 50-day simple moving average of the closing price is $4.74 and its 200-day simple moving average is $2.21. If we look at the stock’s price movements over the week, volatility stands at 344.45%, which decreases to 94.45% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 78.84 to suggest the stock is overbought.
The consensus objective for the share price is $45.46, suggesting that the stock has a potential downside of -5.63% over the period.
The current price level is 374.12%, 913.87%, and 2072.29% away from its SMA20, SMA50, and SMA200 respectively, with the DRUG price moving below the 50-day SMA on current market day. Bright Minds Biosciences Inc (DRUG) stock is up 1828.51% over the week and 3757.03% over the past month. Its price is 3258.04% year-to-date and 3080.13% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to shrink -5.63 percent from here.
Outstanding shares total 3.77M with insiders holding 31.00% of the shares and institutional holders owning 14.06% of the company’s common stock. The company has a return on investment of -59.08% and return on equity of -51.16%. The beta has a value of 4.36. Price to book ratio is 48.09.
